Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial.

Busacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M, Vignali M

Human reproduction (Oxford, England)1 Nov 2001Cited by 76 (Europe PMC)

PMID11679528DOI10.1093/humrep/16.11.2399PepBankPUB-11679528

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, moderate/severe pelvic pain recurred in 23% with leuprolide versus 24% with no treatment, and 18-month cumulative recurrence was 23% versus 29% (not significant).
In plain wordsAfter endometriosis surgery, pelvic pain recurred in 23% with leuprolide and 24% with no treatment; 18-month cumulative rates were 23% and 29% (not significant).
Peptide
Leuprolide
Outcome
DecreaseModerate/severe pelvic pain recurrence during follow-up
Study
n = 89
Comparator
Expectant management
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mg monthly · intramuscular · 3 monthsAs given in this study (human).
Measurements
Pain recurrences
10 women
leuprolide
Pain recurrence rate
23%
leuprolide
Pain recurrences
11 women
no treatment
Pain recurrence rate
24%
no treatment
Cumulative pain recurrence rate at 18 months
23%
leuprolide
Cumulative pain recurrence rate at 18 months
29%
no treatment
Source sentences
Summary
Moderate/severe pelvic pain recurred during the follow-up in 10 (23%) of the women allocated the GnRH analogue and 11 (24%) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29% respectively (not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an…
Report a problemFND-1167952802
02HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, cumulative pain recurrence at 18 months was 23% with leuprolide versus 29% without treatment, without a significant difference.
In plain wordsAfter endometriosis surgery, pain recurrence at 18 months was 23% with leuprolide versus 29% without treatment, with no significant difference.
Peptide
Leuprolide
Outcome
No significant changeCumulative pain recurrence at 18 months
Study
n = 89
Comparator
Expectant management
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mg monthly · intramuscular · 3 monthsAs given in this study (human).
Measurements
Cumulative recurrence
23%
leuprolide at 18 months
Cumulative recurrence
29%
no treatment at 18 months
Source sentences
Summary
Moderate/severe pelvic pain recurred during the follow-up in 10 (23%) of the women allocated the GnRH analogue and 11 (24%) of those allocated no treatment; the cumulative pain recurrence rates at 18 months were 23 and 29% respectively (not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an…
Report a problemFND-1167952803
03HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, objective disease recurrence occurred in four women in each group, or 9%, with leuprolide or expectant management.
In plain wordsAfter endometriosis surgery, disease recurred in 9% of women with leuprolide and 9% with expectant management.
Peptide
Leuprolide
Outcome
No significant changeObjective disease recurrence
Study
n = 89
Comparator
Expectant management
Outcome group
Endometriosis Severity · Reproductive and sexual health
Studied dose
3.75 mg monthly · intramuscular · 3 monthsAs given in this study (human).
Measurements
Recurrences
4 women
leuprolide
Recurrence rate
9%
leuprolide
Recurrences
4 women
no treatment
Recurrence rate
9%
no treatment
Source sentences
Summary
Four women (9%) treated with GnRH analogue and four women (9%) who received no treatment had objective disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an…
Report a problemFND-1167952804
04HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, pregnancy occurred in 33% with leuprolide versus 40% with expectant management during follow-up, without a significant difference.
In plain wordsAfter endometriosis surgery, pregnancy occurred in 33% with leuprolide versus 40% without treatment, with no significant difference.
Peptide
Leuprolide
Outcome
DecreasePregnancy during follow-up
Study
n = 30
Comparator
Expectant management
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg monthly · intramuscular · 3 monthsAs given in this study (human).
Measurements
Pregnancies
5 women
leuprolide, of 15
Pregnancy rate
33%
leuprolide
Pregnancies
6 women
expectant management, of 15
Pregnancy rate
40%
expectant management
Source sentences
Summary
During the follow-up, which ranged from 6-36 months, five (33%) of the 15 women who wanted children and who were allocated the GnRH analogue and six (40%) of the 15 given no treatment became pregnant (not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 89 women were randomized, by computer-generated list, after laparoscopic conservative surgery for symptomatic endometriosis stage III-IV to receive monthly i.m. injections of gonadotrophin-releasing hormone (GnRH) analogue, leuprolide acetate depot (3.75 mg) for 3 months (n = 44) or to an…
Report a problemFND-1167952801

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.